The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m 2 in Spain

By Fonseca Tiago  

Journal of Medical Economics, Vol. 16, Iss. 7, 2013-07 ,pp. : 926-938

Informa Healthcare

Access to resources Recommend Favorite

Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine*

By Fabunmi Rosalind   Nielsen Loretta L.   Quimbo Ralph   Schroeder Brock   Misurski Derek   Wintle Matthew   Wade Ron  

Current Medical Research and Opinion, Vol. 25, Iss. 3, 2009-03 ,pp. : 777-786

Informa Healthcare

Access to resources Recommend Favorite

Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 71, Iss. 12, 2017-12 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open‐label, phase III, non‐inferiority study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 10, 2015-10 ,pp. : 994-1002

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open‐label, phase III, non‐inferiority study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 1462-8902, Iss. 10, 2015-10 ,pp. : 994-1002

John Wiley & Sons Inc

Access to resources Recommend Favorite